311 related articles for article (PubMed ID: 27021205)
1. Overview of elagolix for the treatment of endometriosis.
Melis GB; Neri M; Corda V; Malune ME; Piras B; Pirarba S; Guerriero S; Orrù M; D'Alterio MN; Angioni S; Paoletti AM
Expert Opin Drug Metab Toxicol; 2016 May; 12(5):581-8. PubMed ID: 27021205
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of elagolix in the treatment of endometriosis.
Perricos A; Wenzl R
Expert Opin Pharmacother; 2017 Sep; 18(13):1391-1397. PubMed ID: 28737050
[TBL] [Abstract][Full Text] [Related]
3. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain.
Ezzati M; Carr BR
Womens Health (Lond); 2015 Jan; 11(1):19-28. PubMed ID: 25581052
[TBL] [Abstract][Full Text] [Related]
4. Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature.
Alessandro P; Luigi N; Felice S; Maria PA; Benedetto MG; Stefano A
Arch Gynecol Obstet; 2017 Apr; 295(4):827-832. PubMed ID: 28255765
[TBL] [Abstract][Full Text] [Related]
5. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain.
Barra F; Scala C; Ferrero S
Drugs Today (Barc); 2019 Apr; 55(4):237-246. PubMed ID: 31050692
[TBL] [Abstract][Full Text] [Related]
6. Elagolix for endometriosis: all that glitters is not gold.
Vercellini P; Viganò P; Barbara G; Buggio L; Somigliana E;
Hum Reprod; 2019 Feb; 34(2):193-199. PubMed ID: 30551159
[TBL] [Abstract][Full Text] [Related]
7. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density.
Carr B; Dmowski WP; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
Reprod Sci; 2014 Nov; 21(11):1341-51. PubMed ID: 25249568
[TBL] [Abstract][Full Text] [Related]
8. Elagolix (Orilissa)--an oral GnRH antagonist for endometriosis pain.
Med Lett Drugs Ther; 2018 Sep; 60(1556):158-160. PubMed ID: 30383729
[No Abstract] [Full Text] [Related]
9. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
[TBL] [Abstract][Full Text] [Related]
10. Elagolix as a Novel Treatment for Endometriosis-Related Pain.
Fantasia HC
Nurs Womens Health; 2019 Aug; 23(4):366-369. PubMed ID: 31276630
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain.
Taylor HS; Dun EC; Chwalisz K
Pain Manag; 2019 Sep; 9(5):497-515. PubMed ID: 31434540
[TBL] [Abstract][Full Text] [Related]
12. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
Surrey ES; Soliman AM; Agarwal SK; Snabes MC; Diamond MP
Fertil Steril; 2019 Aug; 112(2):298-304.e3. PubMed ID: 30992150
[TBL] [Abstract][Full Text] [Related]
13. Effect of SKI2670, a novel, orally active, non-peptide GnRH antagonist, on hypothalamic-pituitary-gonadal axis.
Kim SM; Yoo T; Lee SY; Kim EJ; Lee SM; Lee MH; Han MY; Jung SH; Choi JH; Ryu KH; Kim HT
Life Sci; 2015 Oct; 139():166-74. PubMed ID: 26321528
[TBL] [Abstract][Full Text] [Related]
14. The potential role of elagolix for treating uterine bleeding associated to uterine myomas.
Barra F; Vitale SG; Seca M; Scala C; Leone Roberti Maggiore U; Cianci A; Ferrero S
Expert Opin Pharmacother; 2020 Aug; 21(12):1419-1430. PubMed ID: 32401547
[TBL] [Abstract][Full Text] [Related]
15. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
Struthers RS; Nicholls AJ; Grundy J; Chen T; Jimenez R; Yen SS; Bozigian HP
J Clin Endocrinol Metab; 2009 Feb; 94(2):545-51. PubMed ID: 19033369
[TBL] [Abstract][Full Text] [Related]
16. Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis.
Shebley M; Polepally AR; Nader A; Ng JW; Winzenborg I; Klein CE; Noertersheuser P; Gibbs MA; Mostafa NM
Clin Pharmacokinet; 2020 Mar; 59(3):297-309. PubMed ID: 31749075
[TBL] [Abstract][Full Text] [Related]
17. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study.
Diamond MP; Carr B; Dmowski WP; Koltun W; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
Reprod Sci; 2014 Mar; 21(3):363-71. PubMed ID: 23885105
[TBL] [Abstract][Full Text] [Related]
18. A Clinician's Guide to the Treatment of Endometriosis with Elagolix.
Leyland N; Estes SJ; Lessey BA; Advincula AP; Taylor HS
J Womens Health (Larchmt); 2021 Apr; 30(4):569-578. PubMed ID: 32975461
[TBL] [Abstract][Full Text] [Related]
19. Elagolix: First Global Approval.
Lamb YN
Drugs; 2018 Sep; 78(14):1501-1508. PubMed ID: 30194661
[TBL] [Abstract][Full Text] [Related]
20. Clinical Conundrum: A 33-Year-Old With Pain Post-Orgasm and a History of Endometriosis.
Yong PJ
J Obstet Gynaecol Can; 2020 May; 42(5):625-628. PubMed ID: 32414477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
